Clinical Trials Directory

Trials / Terminated

TerminatedNCT02021201

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia, a Comparative Study

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
1 (actual)
Sponsor
Birte Glenthoj · Academic / Other
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This comparison is made between the effects of sertindole and risperidone on vulnerability indicators in schizophrenia. More specifically: the effects of these two antipsychotic compounds on basic processing of incoming information is studied. The investigators expect that the newer antipsychotic sertindole to be more effective in restoring information processing in schizophrenia patients than risperidone.

Detailed description

The study is has a so-called double blind, randomized - yet balanced - cross-over design, in which 24 male patients with schizophrenia are included. After inclusion in the study, patients will be assessed in a test-battery, in which psychophysiological parameters of their basic information capabilities are quantified. Following this, the patients will be treated with either risperidone or sertindole for a period of 10 weeks, after which they will cross-over to the other treatment (the order of treatments is randomized (and balanced)). The battery of tests is repeated after the first and second treatment period. In addition, a second test-battery will be performed at these follow-up intervals, to assess neuropsychological parameters of information processing. To evaluate the extend of the treatment effects, the patients will be matched (age, gender, parental socioeconomic status) to 24 healthy controls.

Conditions

Interventions

TypeNameDescription
DRUGrisperidonePatients with schizophrenia will be treated for 10 weeks treatment with risperidone
DRUGSertindolePatients with schizophrenia will be treated for 10 weeks treatment with serindole

Timeline

Start date
2008-07-01
Primary completion
2013-07-01
Completion
2013-07-01
First posted
2013-12-27
Last updated
2020-03-26

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT02021201. Inclusion in this directory is not an endorsement.